Vitrafy Posts 75% Sales Growth, Eyes FY26 US Market Launches
Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.
- 75% year-on-year sales growth led by aquaculture and human health
- VCU2 hardware and LifeChain software upgrades advancing to commercial launch
- Successful Phase 1 blood platelet study with US Military, Phase 2 underway
- Cash and liquid assets of $29.6 million with runway through 2027
- Expansion of US operations and strategic partnerships planned for FY26
Strong Financial Momentum
Vitrafy Life Sciences Limited (ASX – VFY) has delivered a robust FY25 performance, reporting a 75% increase in sales revenue compared to the previous year. This growth was primarily driven by expansion in the aquaculture sector and completion of key pilot projects in human health. The company ended the year with $29.6 million in cash and liquid assets, providing a solid financial foundation and a cash runway extending through calendar year 2027 despite elevated expenditure planned for FY26.
Technology Development and Commercialisation Progress
Vitrafy is advancing its next-generation cryopreservation technology with significant milestones achieved in hardware and software development. The VCU2 device, designed for commercial readiness, has completed detailed design and entered the build phase, targeting unregulated market release in the first half of FY26 and regulated US market launch in the second half. Complementing this, the LifeChain software upgrade is progressing well, enhancing device functionality and integration capabilities critical for enterprise-scale operations.
Operational Highlights Across Key Markets
The company’s Phase 1 blood platelet study with the US Military yielded outstanding results, surpassing current industry standards and positioning Vitrafy’s technology as a potential game changer for battlefield and resource-constrained medical scenarios. Phase 2 studies are set to commence in early FY26, marking a crucial step towards commercialisation. In animal reproduction, Vitrafy continues to build momentum with ongoing collaborations and pilot programs in bovine and aquaculture sectors, demonstrating competitive advantages in fertilisation and semen motility outcomes.
Strategic Outlook and Leadership Transition
Looking ahead, Vitrafy plans to aggressively scale its US operations and expand paid collaborations in human health. The company aims to capture global commercial opportunities in animal reproduction while progressing regulatory approvals and product launches. Notably, a leadership transition is scheduled with Brent Owens, co-founder and key technology innovator, stepping into the CEO role from September 2025, succeeding Kate Munnings who has a distinguished healthcare leadership background.
Financial Nuances and Investment Considerations
FY25 financial results include several one-off, non-cash items such as an $18.9 million expense related to convertible note conversion and increased share-based payments aligned with new executive incentives. Normalised loss before tax stands at $11.3 million, reflecting ongoing investment in R&D and commercialisation readiness. The company also secured a $4.8 million grant from the Australian Industry Growth Fund to support product development and market growth.
Bottom Line?
Vitrafy’s FY25 achievements set the stage for critical commercial launches and US market expansion in FY26, but investors should watch regulatory progress and Phase 2 study outcomes closely.
Questions in the middle?
- Will Phase 2 blood platelet study results confirm the promising Phase 1 data and accelerate commercial adoption?
- How quickly can Vitrafy scale manufacturing and supply chain capabilities to meet anticipated demand?
- What impact will the leadership transition have on execution of the company’s strategic growth plans?
